Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw

References

• Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2009;38:5–9.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968–71.
   PubMed Web of Science ®Google Scholar
• Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008;13:911–20.
   PubMed Web of Science ®Google Scholar
• Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone diseases. Pharm World Sci 1998;20:206–13.
   PubMedGoogle Scholar
• Russell RGG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25;97–106.
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Molecular mechanisms of action of bisphosphonates. Bone 1999;:24(Suppl 5):73–9.
   Web of Science ®Google Scholar
• Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 2007;1:14–20.
   Google Scholar
• Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007;6:305–13.
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860–7.
   PubMed Web of Science ®Google Scholar
• Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 2007;4:92–100.
   PubMedGoogle Scholar
• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–7.
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433–41.
   PubMed Web of Science ®Google Scholar
• Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999;19:3383–92.
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527–34.
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and treatment. Annu Rev Med 2009;60:85–96.
   PubMed Web of Science ®Google Scholar
• Abildgaard N, Gregersen H, Lund T, Marker P, Preiss B, Schiødt, Bifosfonate-associeret osteonekrose i kæberne hos patienter med myelomatose. 2007; 1–5. www.kaebekirurgi.dk.
   Google Scholar
• Lund T, Gregersen H, Vangsted A, Marker P, Abildgaard N. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma. Ugeskr Laeger 2009;171:50–2.
   PubMedGoogle Scholar
• Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphonates. N Engl J Med 2005;353:99.
   PubMed Web of Science ®Google Scholar
• Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415–23.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785–91.
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826–36.
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Hoffmeister B. Necrosis of the jaw after high-dose bisphosphonate therapy. Dtsch Arzteblatt 2006;103:3078.
   Google Scholar
• Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009;67:2–12.
   PubMed Web of Science ®Google Scholar